Stay updated on JCAR014 and Durvalumab in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the JCAR014 and Durvalumab in Lymphoma Clinical Trial page.

Latest updates to the JCAR014 and Durvalumab in Lymphoma Clinical Trial page
- Check2 days agoChange DetectedRevision updated: v3.5.2 was added and v3.5.0 was removed.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedPage revision updated from v3.4.3 to v3.5.0, indicating a minor metadata update with no changes to study details or results.SummaryDifference0.0%

- Check38 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check66 days agoChange DetectedSite revision v3.4.2 was added and the government funding status notice from v3.4.1 was removed; no study content changes were made. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check73 days agoChange DetectedA government funding lapse notice banner was added and the site was updated to revision 3.4.1, replacing 3.4.0.SummaryDifference0.2%

- Check80 days agoChange DetectedAdded a Show glossary option and new metadata items: Last Update Submitted that Met QC Criteria and No FEAR Act Data, plus a revision note indicating Revision: v3.4.0. Removed the corresponding older items Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.1%

Stay in the know with updates to JCAR014 and Durvalumab in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the JCAR014 and Durvalumab in Lymphoma Clinical Trial page.